US-based company is developing next-generation sequencers, using AI models in the Republic to speed up diagnostics and lower ...

Illumina, Inc., a global genomics and human health leader innovating the future of precision health, announced the launch of BioInsight, a new business within Illumina, developed to meet industry ...

Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the afternoon session after the company announced the launch of BioInsight, a new business unit designed to accelerate drug discovery ...

SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — A year ago, Illumina CEO Jacob Thaysen laid out a plan for the genomics ...

Illumina exceeded Q2FY25 expectations and raised FY25 guidance, driven by resilient Chinese operations and strong clinical market growth, especially in oncology. The company is expanding into ...

Illumina Inc. (NASDAQ:ILMN) is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that ...

Less than two years after Boulder-based biotech firm SomaLogic Inc. merged with Standard BioTools Inc. (Nasdaq: LAB), Illumina Inc. (NASDAQ: ILMN) has inked a deal to absorb SomaLogic’s business in an ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. The deal with ...

Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology ...

Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in ...

Just two months after announcing it would be laying off dozens of its San Diego employees, gene sequencing giant Illumina said it plans let go of 172 more workers. In paperwork filed last week with ...